点击显示 收起
外周血CD3+CD56+T细胞在恶性肿瘤患者中的表现及临床意义
免疫学杂志 2001年第1期第17卷 临床免疫学
作者:冯伟华 王兰兰 武永康 雷松 刘瑾
单位:冯伟华 王兰兰 武永康(华西医科大学附属第一医院临床免疫实验室,四川 成都 610041);雷松(华西医科大学附属第一医院肿瘤生物治疗研究中心,四川 成都 610041);刘瑾(华西医科大学附属第一医院临床免疫实验室,四川 成都 610041)
关键词:CD3+CD56+;恶性肿瘤
摘 要:目的 了解CD3+CD56+T细胞与CD3-CD56+、CD3+CD56-的关系及其在参与恶性肿瘤患者抗肿瘤免疫中的作用。方法 采用流式细胞术对100例恶性肿瘤患者(55例实体瘤患者和45例非实体瘤患者)及46例健康对照组外周血中的CD3+CD56+、CD3-CD56+、CD3+CD56-3类淋巴细胞进行标记分析。结果 在实体瘤和非实体瘤患者组中:CD3+CD56+T细胞均有高表达,2组患者与健康对照组比较均有显著性差异(P<0.01)。CD3+CD56-T细胞在实体瘤组的表达都显著低于非实体瘤组和健康对照组,2组间比较均有显著性差异(P<0.001);而CD3-CD56+NK细胞在2患者组中的表达与健康对照组比较均无显著性差异(P>0.05)。结论 CD3+CD56+T细胞在恶性肿瘤患者外周血中的高表达较CD3-CD56+NK细胞更明显,并且不受恶性肿瘤细胞类型的影响,提示高表达的CD3+CD56+T细胞是参与抗肿瘤免疫的重要表现。
分类号:R392.11 文献标识码:A
文章编号:1000-8861(2001)01-0047-03
Expression and clinical significance of CD3+CD56+ T cell in the peripheral blood on patients with malignant tumor
FENG Wei-hua(Department of Clinical Immunology,the First Affiliated Hospital of West China University of Medical Sciences,Chengdu 610041,China)
WANG Lan-lan(Department of Clinical Immunology,the First Affiliated Hospital of West China University of Medical Sciences,Chengdu 610041,China)
WU Yong-kang(Department of Clinical Immunology,the First Affiliated Hospital of West China University of Medical Sciences,Chengdu 610041,China)
LEI Song(Center for Biotherapy of Cancer,the First Affiliated Hospital of West China University of Medical Sciences,Chengdu 610041,China)
LIU Jin(Department of Clinical Immunology,the First Affiliated Hospital of West China University of Medical Sciences,Chengdu 610041,China)
Abstract:Objective To study the relationship of CD3+CD56+ between CD3-CD56+NK cells and CD3+CD56- T cells and anti-tumor activity of CD3+CD56+ T lymphocytes of patients with malignant tumor.Methods We analysed CD3-CD56+,CD3+CD56-,CD3+CD56+ T lymphocytes in blood samples of 100 patients(from 55 soft tumor patients and 45 non-soft tumor patients)and in 46 healthy control by flow cytometry.Results High expression of CD3+CD56+ in T cells was found both in soft tumor group and in non-soft one,there was significant difference between both the two groups and the control group(P<0.01).The expression of CD3+CD56+ T cells was much lower in soft tumor group than the non-soft tumor group and healthy control(P<0.001),no significant difference was found in the expression of CD3-CD56+NK cells among the three groups(P>0.05).Conclusion The CD3+CD56+expression was more abvious in the peripheral blood of patients with malignant tumor than CD3-CD56+ NK cell.It was not influenced by the type of malignant tumor.It shows that the high expression of CD3+CD56+ T cells is one of the most important factors that make T lymphocytes to exert anti-tumor immunological function.
Keywords:CD3+CD56+; malignant tumor
作者简介:冯伟华 (1968-),男,四川彭州市人,检验技师,大专,主要从事临床免疫检验的研究。Tel:(028)5422752;E-mail:linmianshi@sohu.com参考文献:
[1]Jin Y,Fuller L,Carreno M,et al.The regulation of phenotype and function of human liver CD3+/CD56+lymphocytes,and cells that also co-express CD8 by IL-2,IL-12 and anti-CD3 monoclonal antibody [J].Hum Immunol,1998,39(6):352-362.
[2]Finke S,Trojaneck B,Hefterora P et al.Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunololgic effector cells by receptor mediated transfection with the interleukin-7 gene [J].Gene ther,1998,5(1):31-39.
[3]Hoyle C,Bangs CD,Chang P,et al.Expansion of philade phia chromosome negative CD+3CD+56 cytotoxin cells from chronic myeloid leukemia patients:in vitro and in vivo efficacy in severe combined immunodefeciency disease mice [J].Blood,1998,92(9):3 318-3 327.
[4]Euhus DM,Kimura L,Arnold B.Expansion of CD3+CD56+ lymphocytes correlates [J].Arm Surg Oncol.1997,4(5):432-439.
[5]Fujimiya Y,Suzuki Y,Katakura R,et al.In vitro interleukin 12 activation of peripheral blood CD+3CD-56 and CD3+CD56- gammadelta T cells from glioblastoma patients [J].Clin Cancer Res,1997,3(4):633-643.
收稿日期:2000年1月13日
修稿日期:2000年8月28日
出版日期:2001年1月15日